Physician profile
Ashutosh Niraj
NPI 1407032634
$1,758.89
in general payments reported to CMS, 2019-2025
25 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.38 · 2020: $27.60 · 2021: $409 · 2022: $278 · 2023: $360 · 2024: $375 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $446.41 | 2023-2024 | Xcopri |
| Novartis Pharmaceuticals Corporation | $272.41 | 2019-2025 | |
| Boston Scientific Corporation | $105.10 | 2024-2025 | Lux-Dx Insertable Cardiac Monitor, Bodyguardian |
| Eisai INC. | $96.65 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $79.16 | 2021-2022 | |
| Aucta Pharmaceuticals, INC. | $77.18 | 2025 | Motpoly Xr |
| Aquestive Therapeutics, INC. | $72.46 | 2020-2022 | |
| Abbott Laboratories | $61.64 | 2021 | |
| Ucb, INC. | $50.94 | 2024-2025 | Fintepla |
| Acadia Pharmaceuticals INC | $48.52 | 2025 | Daybue |
| Harmony Biosciences LLC | $47.14 | 2022 | |
| Sumitomo Pharma America, INC. | $45.93 | 2023 | Aptiom |
| Scpharmaceuticals INC. | $41.89 | 2025 | |
| Inspire Medical Systems, INC. | $40.94 | 2023 | Inspire |
| Amgen INC. | $40.90 | 2021-2024 | Tavneos |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $37.91 | 2021-2022 | |
| Averitas Pharma INC. | $30.88 | 2025 | Qutenza |
| Merck Sharp & Dohme LLC | $28.86 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.36 | 2022 | |
| Alnylam Pharmaceuticals INC. | $22.68 | 2024 | Onpattro |
| Zoll Respicardia, INC. | $21.36 | 2024 | Remede System |
| Livanova USA, INC. | $17.96 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Janssen Pharmaceuticals, INC | $15.85 | 2021 | |
| Shield Therapeutics INC | $15.41 | 2023 | Accrufer |
| Astrazeneca Pharmaceuticals Lp | $14.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashutosh Niraj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.